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Aluminum-containing adjuvants are widely used in preventive vaccines against infectious
diseases and in preparations for allergy immunotherapy. The mechanism by which they
enhance the immune response remains poorly understood. Aluminum adjuvants selec-
tively stimulate a Th2 immune response upon injection of mice and a mixed response
in human beings. They support activation of CD8 T cells, but these cells do not undergo
terminal differentiation to cytotoxic T cells. Adsorption of antigens to aluminum adjuvants
enhances the immune response by facilitating phagocytosis and slowing the diffusion of
antigens from the injection site which allows time for inflammatory cells to accumulate.
The adsorptive strength is important as high affinity interactions interfere with the immune
response. Adsorption can also affect the physical and chemical stability of antigens. Alu-
minum adjuvants activate dendritic cells via direct and indirect mechanisms. Phagocytosis
of aluminum adjuvants followed by disruption of the phagolysosome activates NLRP3-
inflammasomes resulting in the release of active IL-1β and IL-18. Aluminum adjuvants also
activate dendritic cells by binding to membrane lipid rafts. Injection of aluminum-adjuvanted
vaccines causes the release of uric acid, DNA, and ATP from damaged cells which in turn
activate dendritic cells. The use of aluminum adjuvant is limited by weak stimulation of
cell-mediated immunity. This can be enhanced by addition of other immunomodulatory
molecules. Adsorption of these molecules is determined by the same mechanisms that
control adsorption of antigens and can affect the efficacy of such combination adjuvants.
The widespread use of aluminum adjuvants can be attributed in part to the excellent safety
record based on a 70-year history of use. They cause local inflammation at the injection
site, but also reduce the severity of systemic and local reactions by binding biologically
active molecules in vaccines.
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INTRODUCTION
Adjuvants are substances added to vaccines to enhance and direct
the immune response. They are often necessary for the induc-
tion of a protective immune response against recombinant sub-
unit antigens and protein toxins. The immunostimulatory effect
of aluminum-containing adjuvants was first described in 1926
(Glenny et al., 1926). The investigators demonstrated that injec-
tion of diphtheria toxoid precipitated with alum (potassium alu-
minum sulfate) induced a stronger antibody response than soluble
toxoid in guinea pigs. Subsequent studies showed that alum-
precipitated diphtheria toxoid and tetanus toxoid also enhance
protective immune responses in people (Jones, 1936; Volk and
Bunney, 1942). Aluminum adjuvants are currently used in sev-
eral human vaccines against infectious diseases, including vaccines
against diphtheria, tetanus, pertussis, hepatitis B, anthrax, and dis-
eases caused by Haemophilus influenzae and human papilloma
virus (Baylor et al., 2002; Frazer et al., 2011). They are also used in
immunotherapy for allergic diseases (Francis and Durham, 2004;
Eifan et al., 2011), and are being evaluated for immunotherapy
against autoimmune diabetes mellitus (Wherrett et al., 2011).
Certain veterinary vaccines for protection of food animals and
companion animals from infectious diseases are formulated with
aluminum adjuvants (Lindblad, 2004).
Vaccines containing aluminum adjuvants induce an effective
immune response that is primarily antibody-mediated. In spite
of their longstanding use, the mechanism by which aluminum
adjuvants selectively enhance the immune response is poorly
understood. It is now generally accepted that the innate immune
system plays a critical role in initiating and directing the adap-
tive immune response. Adjuvants enhance the adaptive immune
response by activation of innate immune cells that in turn pro-
vides signals for activation of lymphocytes. Studies over the past
decade have shed new light on the interaction of aluminum adju-
vants with antigen-presenting cells and inflammatory cells, both of
which appear to be critical in inducing and shaping the immune
response. The possible mechanisms by which aluminum adju-
vants enhance the immune response have been subject of several
recent reviews (Aimanianda et al., 2009; Marrack et al., 2009; Kool
et al., 2012). I will review the physical and chemical characteristics
of aluminum adjuvants and their interaction with antigens and
other immunomodulatory molecules, and discuss this along with
the mechanism of immunostimulation. Aluminum adjuvants owe
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their popularity in part to their relatively low cost and long stand-
ing safety record (Lindblad, 2004). This review will conclude with
a brief discussion of the safety of aluminum adjuvants.
WHAT ARE ALUMINUM-CONTAINING ADJUVANTS?
Aluminum-containing adjuvants are often simply referred to as
“alum.” This term should be avoided for two reasons. First, alum
is the name of a specific chemical compound, hydrated potassium
aluminum sulfate, KAl(SO4)2·12 H2O. Precipitation of a solution
of alum and antigen was originally used for the preparation of
aluminum-adjuvanted vaccines. The chemical composition of the
aluminum precipitate depends on the type of ions present in the
antigen solution. The precipitation method is difficult to repro-
duce in a consistent manner and has largely been replaced by
adsorption of antigens to aluminum-containing gels. The second
reason to avoid the term alum is that it fails to specify which
type of aluminum-containing adjuvant was used for the vaccine
preparation. The two main types of aluminum adjuvants that are
commercially available are aluminum hydroxide adjuvant (AH)
and aluminum phosphate adjuvant (AP). The physical and chem-
ical composition of AH and AP are quite different and this has
important implications for the formulation with antigens (Shi-
rodkar et al., 1990; Lindblad, 2004; Hem and HogenEsch, 2007).
AH is chemically aluminum oxyhydroxide, Al(O)OH, rather than
Al(OH)3. It has a crystalline structure and is composed of pri-
mary needle-like nanoparticles that are 4.5 nm× 2.2 nm× 10 nm
in size (Johnston et al., 2002). The nanoparticles form loose aggre-
gates that can be up to 17µm in size (Morefield et al., 2005).
The surface area of AH is extremely large, estimated at 510 m2/g
(Johnston et al., 2002). The point-of-zero charge (PZC) of AH is
11.4 giving the surface a positive charge at neutral pH. The other
commercially available aluminum adjuvant is AP, which is chemi-
cally aluminum hydroxyphosphate, Al(OH)x(PO4)y. The ratio of
surface hydroxyls and phosphate varies depending on the man-
ufacturing conditions resulting in a PZC that varies between 4.5
and 5.5 and a negative charge at neutral pH. In contrast to the
crystalline structure of AH, AP is amorphous by X-ray diffrac-
tion analysis (Burrell et al., 2000a). The primary AP particles are
plate-like, 50 nm in diameter, and form loose aggregates that are
approximately 3µm in size (Burrell et al., 2000b; Morefield et al.,
2005). The opposite surface charges of AH and AP in the pH range
used for vaccine formulations affect the electrostatic interactions
between the adjuvants and vaccine antigens as discussed in more
detail below. Another difference between AH and AP is that AP
more readily dissolves following injection. This was demonstrated
in vivo with 26Al-labeled AH and AP injected intramuscularly into
rabbits. Analysis of blood and tissue samples over a 28 day period
revealed that about three times as much 26Al was released from AP
than from AH (Flarend et al., 1997).
Another commercially available aluminum-containing adju-
vant is Imject®Alum. It is commonly used for experimental and
basic immunological studies, but it is chemically very different
from the AH and AP adjuvants that are used in human and vet-
erinary vaccines. Imject®Alum consists of crystalline magnesium
hydroxide (40 mg/mL) and amorphous aluminum hydroxycar-
bonate (40 mg/mL; Hem et al., 2007). The composition of the alu-
minum component is different from AH and AP, while magnesium
by itself has effects on the immune system and inflammatory
response (Exley et al., 2010). Magnesium ions inhibit macrophage
activation by blocking certain calcium channels and this con-
tributes to the anti-inflammatory effect of magnesium (Lee et al.,
2011). While Imject®Alum clearly has adjuvant activity, it should
not be used in experiments aimed at elucidating the mechanism
of aluminum adjuvants in licensed human vaccines.
IMMUNOSTIMULATION BY ALUMINUM-CONTAINING
ADJUVANTS
Highly purified vaccine antigens are usually poorly immunogenic
because of insufficient stimulation of the innate immune sys-
tem. Aluminum adjuvants are included in vaccines to enhance the
immune response to purified viral and bacterial antigens such as
hepatitis B surface antigen (HBsAg), human papilloma virus cap-
sid proteins and inactivated bacterial toxins. Their incorporation
in vaccine formulations increases the concentration and avidity of
antigen-specific antibodies (Petty and Steward, 1977; Lefeber et al.,
2003). The level of immunity that is obtained by vaccination varies
markedly among individuals due to genetically determined poly-
morphisms in molecules that play a role in the immune response,
stochastic variation in the repertoire of antigen-specific receptors,
and non-genetic factors such as age, nutritional status, and envi-
ronmental influences. Adjuvants increase the proportion of the
vaccinated population that develops a protective immune response
and the duration of the immune response, and may allow for
fewer immunizations and a reduced amount of antigen per dose
(Coffman et al., 2010). Adjuvants also shape the type of immune
response that develops in response to the antigens included in the
vaccine. Aluminum adjuvants primarily enhance antibody pro-
duction and have little effect on the cell-mediated arm of the
immune response. Recent studies have begun to shed light on the
complex mechanisms that appear to underlie the immunostimula-
tory effect of aluminum adjuvants. In reviewing these studies, one
should keep in mind that many experiments were carried out using
intraperitoneal injections of Imject®Alum in a few inbred strains
of mice. Although elegant and informative in terms of the biology,
the relevance to the mechanisms involved in the immune response
to aluminum adjuvants injected intramuscularly in human beings
remains to be determined.
THE IMMUNE RESPONSE TO ALUMINUM-ADJUVANTED
VACCINES
Immunization with aluminum-adjuvanted vaccines induces
antibody-mediated protection directed by CD4 T cells. Naïve CD4
T cells differentiate into effector cells with specific functions based
on molecular signals provided by dendritic cells and the local
microenvironment in which the differentiation takes place. There
is considerable plasticity among effector CD4 T cells, but they can
be divided into subpopulations based on secretion of particular
combinations of cytokines and on expression of distinct surface
markers and transcription factors (Zhu et al., 2010; Okoye and
Wilson, 2011). The effector CD4 T cells were initially divided into
Th1 and Th2 cells (Mosmann et al., 1986). Th1 cells are character-
ized by the secretion of IFN-γ and expression of the transcription
factor T-bet, and Th2 cells by the secretion of IL-4, IL-5, and IL-
13, and the expression of GATA-3 (Zhu et al., 2010). Around 2003,
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two new subpopulations of CD4 effector T cells were recognized,
namely Th17 cells which secrete the cytokines IL-17A and IL-22
and express RORγt, and inducible regulatory T cells (iTreg) that
express Foxp3 (Zhu et al., 2010). More recently, follicular T helper
cells (TFH) were identified as a separate CD4 T cell subpopulation
based on the expression of CXCR5, PD1, and the transcription
factor BCL-6 (Johnston et al., 2009; Nurieva et al., 2009; Yu et al.,
2009). These studies suggested that TFH rather than Th2 cells are
critical for antibody-mediated immune responses. Earlier reports
showed that aluminum adjuvants direct differentiation of CD4
T cells to Th2 effector cells in vivo and in vitro and do not sup-
port the differentiation of Th1 cells (Brewer et al., 1996; Comoy
et al., 1997; Cunningham et al., 2004; Sokolovska et al., 2007). The
ability of aluminum adjuvants to induce a Th2-biased immune
response is the basis of the common use of these adjuvants in
the induction of allergic diseases in mouse models. More recent
studies showed that injection of mice with alum-precipitated pro-
tein induced a marked increase of antigen-specific TFH cells in the
draining lymph nodes (Serre et al., 2011a,b). Comparison of TFH
and non-TFH CD4 T cells suggested that TFH cells rather than Th2
cells were the major subpopulation of IL-4-secreting CD4 T cells
(Serre et al., 2011a). Taken together these older and more recent
studies suggest that aluminum adjuvants induce the differentia-
tion of Th2 cells that drive an eosinophilic inflammatory response
and TFH cells that stimulate antibody production. In addition
aluminum-adjuvanted vaccines may support the differentiation
of Th17 cells in mice. These cells are thought to be important in
the protection against extracellular bacterial and fungal infections.
A vaccine containing a yeast-expressed recombinant protein with
AH induced protection against Staphylococcus aureus and Candida
albicans. Protection was dependent on IL-17A and induction of
Th17 cells in draining lymph nodes was demonstrated (Lin et al.,
2009). A whole cell Streptococcus pneumoniae vaccine formulated
with AH induced a robust IL-17A response in mice (HogenEsch
et al., 2011). This response was not observed with AP or in the
absence of AH. Earlier work had indicated that IL-17A is critical
for protection against colonization following vaccination (Lu et al.,
2008). These two examples of AH-supported Th17 induction used
either a very high dose (300µg) of a highly mannosylated protein
or a poorly defined mixture of antigens. It remains to be seen
if aluminum adjuvants support Th17 differentiation when com-
bined with more conventional protein antigens. Interestingly, the
induction of Th17 differentiation can be driven by IL-1 and IL-18
(Conforti-Andreoni et al., 2011), two cytokines that are induced
by aluminum adjuvants as discussed in more detail below.
Evidence for a Th2-biased immune response in people is less
convincing and the few available studies suggest a response dri-
ven by a mixed population of Th1, Th2, and possibly other
CD4 effector cells. Peripheral blood mononuclear cells (PBMC)
isolated from individuals immunized with keyhole limpet hemo-
cyanin (KLH) combined with AH secreted mostly IL-5, IL-10, and
IL-13 upon restimulation in vitro and induced IgG1 and IgG4
anti-KLH antibodies consistent with a Th2 response (Spazierer
et al., 2009). However, restimulation of PBMC from the same
volunteers with tetanus toxoid induced IFN-γ secretion and no
IL-13 suggestive of a Th1 response. Although the vaccination
and natural exposure histories were not specified, most tetanus
vaccines contain aluminum adjuvants suggesting that aluminum-
adjuvanted tetanus vaccines stimulated a Th1-biased response.
Aluminum adjuvants are also used in immunotherapy of autoim-
mune and allergic diseases. Two subcutaneous injections of the
65 kDa isoform of glutamic acid dehydrogenase 65 (GAD65),
an autoantigen in type 1 diabetes mellitus, formulated with AH
(0.5 mg aluminum/dose) induced an antibody and T cell response.
The T cell response was mixed with a significant increase of ex
vivo secretion of IFN-γ, IL-17, IL-10, and type 2 cytokines, and
development of FoxP3+, CD25+ CD4 T cells (Ludvigsson et al.,
2008; Hjorth et al., 2011). A phase II clinical trial of GAD65 with
AH failed to show efficacy in halting or delaying the develop-
ment of diabetes mellitus (Wherrett et al., 2011). Preparations of
allergens with aluminum hydroxide adjuvant are widely used for
subcutaneous desensitization of patients with allergies (Francis
and Durham, 2004). Possible explanations for the effect of this
treatment include a shift away from Th2 responses and induc-
tion of IgE-blocking IgG antibodies and regulatory T cells (Eifan
et al., 2011). In vitro exposure of PBMC from allergic individuals
to allergen and aluminum hydroxide adjuvant reduced the secre-
tion of IL-5 and IL-13 in comparison with allergen only, while
the adjuvant had little effect on the secretion of IL-10, IL-12, and
IFN-γ (Wilcock et al., 2004).
Proteins taken up by antigen-presenting cells are typically
processed and peptides presented via MHC II molecules to CD4
T cells. In some cases, peptides from extracellular proteins can
enter the MHC I presentation pathway and be presented to CD8 T
cells. Dendritic cells are most efficient among antigen-presenting
cells in cross-presentation of antigens (Joffre et al., 2012). The
mechanisms involved in cross-presentation are not completely
understood and vary depending on the antigen and delivery system
(Compeer et al., 2012; Joffre et al., 2012). Immunization of mice
with aluminum-adjuvanted vaccines does not effectively prime the
development of cytotoxic T cells (CTLs; Dillon et al., 1992; Kwissa
et al., 2003; Garulli et al., 2008). However, following immunization
of ovalbumin (OVA) with AH or alum-precipitated OVA, OVA-
specific CD8 T cells are activated and proliferate. The activated T
cells express IFN-γ, but fail to differentiate into CTLs (McKee et al.,
2009; Serre et al., 2010; MacLeod et al., 2011). Cross-presentation
of OVA was dependent on CD8+ dendritic cells, a subset of DCs
specialized in cross-presentation (MacLeod et al., 2011). The addi-
tion of a TLR4 agonist, monophosphoryl lipid A (MPLA), was
required for induction of CTL differentiation (MacLeod et al.,
2011). MPLA induces the secretion of IL-12 which is necessary for
the terminal differentiation of CD8 T cells (Curtsinger et al., 2003;
Pearce and Shen, 2007).
ROLE OF ADSORPTION IN THE IMMUNOSTIMULATING
EFFECT OF ALUMINUM ADJUVANTS
Antigens adsorb to aluminum adjuvants via hydrophobic and
van der Waals forces, via electrostatic attraction and by ligand
exchange (Hem and HogenEsch, 2007). Electrostatic attraction
occurs when antigen and the adjuvant surface have opposite
charges. The surface of AH is positively charged at neutral pH
and attracts antigens with an isoelectric point (i.e.p.) less than
7, whereas AP is negatively charged and attracts proteins with
an i.e.p. greater than 7 (Figure 1). Fusion proteins can consist
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FIGURE 1 |The critical role of the type of aluminum adjuvant and pH in
the adsorption of vaccine antigens via electrostatic mechanisms. The
point-of-zero-charge (PZC) of aluminum hydroxide adjuvant (AH) is 11.4 and
that of aluminum phosphate adjuvant (AP) is approximately 5. At the pH of
vaccine formulations (about 6–7.5), AH has a positively charged surface and
attracts negatively charged proteins such as ovalbumin with a isoelectric
point of 4.6. The surface of AP is negatively charged and it repels similarly
charged proteins (OVA) and binds proteins with a high i.e.p. such as hen
egg lysozyme (lys).
of peptides with opposite i.e.p.’s resulting in a bipolar molecule.
This likely affects the orientation of the antigens on the adju-
vant surface when adsorbed to AH vs. AP, but no effect on the
immune response was observed (Dagouassat et al., 2001). Anti-
gens adsorbed via electrostatic mechanisms are quickly released
upon exposure to interstitial fluid (Iyer et al., 2003; de Veer et al.,
2010). Ligand exchange is the strongest attractive force between
antigens and aluminum adjuvants. Aluminum has a higher affin-
ity for phosphate than for hydroxyls and phosphates will displace
surface hydroxyls on aluminum adjuvants. Molecules with mul-
tiple terminal phosphate groups have a very high affinity for AH
as they adsorb via ligand exchange. The affinity can be modu-
lated by pre-treatment of AH with phosphate buffer resulting in
replacement of hydroxyls by phosphates. Antigens adsorbed via
ligand exchange mechanism are slowly released from the adjuvant
following exposure to interstitial fluid.
Adsorption is generally thought to be important for the
immunostimulatory effect of aluminum adjuvants (Gupta, 1998).
The particulate nature of adsorbed antigens facilitates uptake by
antigen-presenting cells via phagocytosis (Mannhalter et al., 1985;
Morefield et al., 2005). Adsorbed antigens are more slowly released
from the injection site (Leeling et al., 1979; Weissburg et al., 1995;
Noe et al., 2010), but the kinetics are highly dependent on the
strength of the adsorption. Electrostatically adsorbed antigens
are rapidly released and diffuse away from the injection site at a
higher rate than antigens adsorbed via ligand exchange (Noe et al.,
2010). The retention of antigens at the injection site allows time
for inflammatory cells and antigen-presenting cells to accumulate
at the injection site and to interact with vaccine antigens. This
is consistent with early experiments by Holt who demonstrated
that removal of the injection site within 4 days after subcutaneous
injection of guinea pigs with diphtheria toxoid adsorbed to AP
interfered with the development of an antibody response. In con-
trast, removal of the injected ear 2 h after subcutaneous injection
of AH with antigen did not affect the magnitude or duration of
the immune response (Hutchison et al., 2012). This would sug-
gest that neither adsorption nor the local inflammatory response
at the injection site is necessary for the immunostimulatory effect
of aluminum adjuvants. It is difficult to reconcile this with the
studies by Holt. Unfortunately, the results of ear ablation were not
reported following injection of antigen only. It is possible that tis-
sue trauma resulting from resection of the ear induced sufficient
inflammatory signals to stimulate the development of the immune
response.
Aluminum adjuvants can also stimulate the immune response
to non-adsorbed antigens (Berthold et al., 2005; Romero Mendez
et al., 2007). The adjuvant and antigen need to be injected at the
same site in order for the enhanced immunogenicity to occur
(Chang et al., 2001; Eisenbarth et al., 2008). The need for adsorp-
tion appears to decrease with larger antigen doses (Berthold et al.,
2005). This is probably caused by interactions between the anti-
gen and the extracellular matrix resulting in retention of a por-
tion of the injected antigen. This is indicated by the kinetics of
subcutaneously injected soluble protein (Noe et al., 2010) and fur-
ther supported by pharmacokinetic studies with subcutaneously
injected monoclonal antibodies showing significant retention of
protein at the site of injection (Joshi et al., 2006; Xu et al., 2010).
In vitro experiments suggests that a variable but significant por-
tion of monoclonal antibodies is retained at the injection site via
electrostatic interactions with the extracellular matrix (Mach et al.,
2011). This is also likely to happen with certain vaccine antigens.
When higher doses of non-adsorbed antigens are used, a sufficient
amount of antigen is retained at the injection site for interaction
with inflammatory cells recruited in response to the co-injected
aluminum adjuvants. On the other hand, too tight adsorption
has a negative effect on the immunogenicity of the vaccine as
demonstrated most clearly with alpha-casein, a small 24 kDa pro-
tein with eight phosphate groups allowing for extensive ligand
exchange interactions with AH (Hansen et al., 2007). The adsorp-
tive strength (affinity) of alpha-casein for AH could be reduced by
pre-treatment of AH with phosphate buffer and this resulted in an
increased antibody and T cell response (Hansen et al., 2007). High
adsorptive strength probably interferes with antigen processing
and prevents T cell activation. Similarly, the adsorptive strength of
HBsAg which is embedded in a phospholipid membrane can be
reduced by pre-treatment of AH with phosphate. The formulation
of HBsAg with phosphate-treated AH or AP induced a greater anti-
body response than HBsAg with AH (Kwissa et al., 2003; Hansen
et al., 2009).
While adsorption to aluminum adjuvants usually enhances the
immune response to antigens, it can affect the physical and chem-
ical stability of antigens over time (Clapp et al., 2011). Proteins
are subjected to various degradation processes including deami-
dation, oxidation, and hydrolysis that are dependent on pH and
temperature (Manning et al., 2010). The pH of the microenviron-
ment of the charged aluminum adjuvant surface is different from
the bulk formulation pH because of attraction of ions from the
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solution. The positively charged surface of AH attracts negatively
charged hydroxyl ions increasing the microenvironment pH by as
much as two units (Wittayanukulluk et al., 2004). This change in
pH can accelerate the degradation of adsorbed antigens. Proteins
adsorbed onto solid surface also tend to unfold causing a loss of
the secondary and tertiary structure (Manning et al., 2010). This
often results in exposure of hydrophobic parts of the proteins and
an increase of hydrophobic interactions with aluminum adjuvants.
This likely contributes to reduced desorption of antigens from alu-
minum adjuvants in aged vaccines (Shi et al., 2001a; Vessely et al.,
2009). Several biophysical assays including differential scanning
calorimetry, intrinsic (tryptophan) and extrinsic fluorescence, and
Fourier transform infrared spectroscopy, have been successfully
employed in recent years to assess the conformational stability of
proteins adsorbed onto aluminum adjuvants (Jones et al., 2005;
Peek et al., 2007; Ausar et al., 2011; Iyer et al., 2012; Ljutic et al.,
2012). Adsorption usually decreases the stability of proteins, but
increased stability of AH-adsorbed proteins was observed in a few
cases (Estey et al., 2009; Iyer et al., 2012). Few studies have directly
examined the effect of the adsorption-induced structural changes
on the immune response to the vaccine. Studies of freshly prepared
AH-adsorbed recombinant protective antigen (rPA) of Bacillus
anthracis (rPA) identified minimal changes in the protein structure
(Soliakov et al., 2012). However, others observed marked struc-
tural changes in rPA upon aging the vaccine for 3 weeks, and this
was associated with a decrease of neutralizing antibodies in mice
injected with the aged formulation compared with the freshly pre-
pared vaccine (Wagner et al., 2012). Adsorption-induced changes
in the protein structure can be reduced by formulation of the vac-
cine with a phosphate buffer which alters the microenvironment
pH and may reduce the adsorptive strength (Wittayanukulluk
et al., 2004; Iyer et al., 2012). An alternative strategy is to add
stabilizers such as sucrose, sorbitol and trehalose to the vaccine
formulation (Peek et al., 2007; Iyer et al., 2012). These compounds
stabilize proteins in solution and adsorbed onto aluminum adju-
vants, but their addition to vaccine formulation scan decrease the
adsorption of protein antigens (Peek et al., 2007; Vessely et al.,
2007).
ROLE OF INFLAMMATION IN THE IMMUNOSTIMULATING
EFFECT OF ALUMINUM ADJUVANTS
Inflammation induced at the injection site is thought to be impor-
tant for the adjuvant effect of AH and AP. Intramuscular injection
of mice and guinea pigs with tetanus toxoid vaccines with AH
resulted in necrosis of muscle fibers and inflammation with edema
and infiltration of leukocytes (Goto and Akama, 1982; Goto et al.,
1997). This is associated with increased expression of mRNAs
for chemokines, cytokines, and cell adhesion molecules (Mosca
et al., 2008). The majority of leukocytes were neutrophils during
the first 72 h, followed by accumulation of increasing numbers of
macrophages at 1 week after injection (Goto and Akama, 1982).
The macrophages form granulomas that can persist for months
(Goto and Akama, 1982; Verdier et al., 2005). Although these
granulomas contain aluminum adjuvant and antigen, their pres-
ence is not required for the immune response as removal of the
injection site after 7 days did not interfere with the magnitude or
duration of the immune response (Holt, 1950). Goto and Akama
(1982) found few eosinophils at the injection site in contrast to
an earlier report that approximately 25% of the inflammatory
cells were eosinophils 4 days following intramuscular injection of
tetanus toxoid with AH or AP (Walls, 1977). In a more recent
study, the composition of the inflammatory cells following intra-
muscular injection of mice with OVA and AH was analyzed by
flow cytometry at 24 h after injection (Calabro et al., 2011). The
majority of infiltrating cells were neutrophils and inflammatory
monocytes with few eosinophils (Calabro et al., 2011). Other stud-
ies examined the kinetics of the inflammatory response following
intraperitoneal injection of aluminum-containing adjuvants. This
route of injection allows for recovery of cells without the need of
enzymatic treatment and for quantification of the concentration
of cytokines in the peritoneal fluid, but of course is different from
the normal route of injection of vaccines. Injection of aluminum-
containing adjuvant with or without protein antigens such as OVA
resulted in rapid secretion of chemokines and cytokines into the
peritoneal fluid (Kool et al., 2008b; McKee et al., 2009; Korsholm
et al., 2010). An increase of neutrophils occurred as early as 6 h
after injection (Kool et al., 2008b; Korsholm et al., 2010). This
was followed by an increased number of inflammatory mono-
cytes and myeloid and plasmacytoid dendritic cells. The number of
eosinophils was increased at 24 h after injection (Walls, 1977; Kool
et al., 2008b; McKee et al., 2008, 2009; Korsholm et al., 2010), and
continued to increase reaching a peak at 4–8 days (Walls, 1977).
The 24-h accumulation of eosinophils was partially dependent
on mast cell-derived IL-5 and histamine and unidentified factors
secreted by macrophages (McKee et al., 2009). The increase of
eosinophils in response to AH was diminished in thymectomized
mice suggesting a role for T cells (Walls, 1977). Neutrophils orches-
trate the recruitment of inflammatory monocytes via the release
of granule proteins such as azurocidin and LL-37 (Soehnlein and
Lindbom, 2010). In spite of this role, depletion of neutrophils with
monoclonal antibodies prior to immunization with lysozyme and
aluminum adjuvant increased activation of antigen-specific T cells
and the antibody response (Yang et al., 2010). The neutrophils
appeared to compete with antigen-presenting cells for antigen
and to interfere directly with antigen presentation (Yang et al.,
2010). Inflammatory monocytes recruited to the injection site can
differentiate into macrophages and dendritic cells. They take up
antigen and transport it to the draining lymph node while under-
going differentiation into dendritic cells. This is consistent with
in vitro experiments which show that aluminum adjuvants induce
differentiation of human monocytes to cells with phenotypic and
functional characteristics of dendritic cells (Ulanova et al., 2001;
Rimaniol et al., 2004; Seubert et al., 2008). Depletion of peri-
toneal macrophages with clodronate-containing liposomes did
not affect the immune response to intraperitoneally injected OVA
with aluminum adjuvant (McKee et al., 2009). However, deple-
tion of dendritic cells nearly completely abolished T cell responses
and antibody production indicating a critical role for dendritic
cells in the immune response to aluminum-adjuvanted vaccines
(Kool et al., 2008b). Intraperitoneal injection of aluminum adju-
vant also induced an increase of Gr-1+, IL-4+ cells in the spleen,
most of which are eosinophils (Jordan et al., 2004; Wang and
Weller, 2008). Although these eosinophils appeared to enhance
B cell priming and early IgM antibody production, the absence of
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eosinophils did not affect the quality or magnitude of the antibody
response to aluminum-adjuvanted vaccines (McKee et al., 2009).
Recently, basophils were reported to serve as antigen-presenting
cells for Th2-biased immune responses (Perrigoue et al., 2009;
Sokol et al., 2009; Yoshimoto et al., 2009). These reports were
based on depletion of basophils with anti-FcεRI (Mar-1) anti-
bodies. It was subsequently shown that mice have a subset of
FcεRI+ dendritic cells that are depleted by Mar-1 antibody treat-
ment in addition to basophils (Hammad et al., 2010). Genetically
engineered mice that lack basophils are capable of mounting a
normal antibody response to aluminum-adjuvanted vaccines indi-
cating that basophils are not necessary (Ohnmacht et al., 2010).
Thus, among the different cells recruited to the vaccine injection
site, the recruitment of inflammatory monocytes and subsequent
differentiation into dendritic cells appears to be critical for the
development of the immune response to aluminum-adjuvanted
vaccines.
ALUMINUM ADJUVANTS AND DENDRITIC CELLS
In vitro studies with mouse bone marrow-derived dendritic cells
have demonstrated that aluminum adjuvants have a direct effect
on dendritic cells. They increase the uptake of antigens and the
presentation and activation of antigen-specific T cells (Morefield
et al., 2005; Sokolovska et al., 2007; Ghimire et al., 2012). Both
AH and AP induce secretion of IL-1β and IL-18 by dendritic cells
(Li et al., 2007; Sokolovska et al., 2007). This also occurred in
MyD88-deficient dendritic cells consistent with observations that
immunostimulation by aluminum adjuvants in vivo was indepen-
dent of signaling through Toll-like receptors (Schnare et al., 2001;
Gavin et al., 2006). Dendritic cells incubated with aluminum adju-
vants and OVA induced differentiation of naïve OVA-specific CD4
T cells to Th2 cells in vitro. This effect was blocked by antibod-
ies against IL-1β and IL-18 suggesting a role for these cytokines
in Th2 differentiation (Sokolovska et al., 2007). IL-1β and IL-18
are synthesized by cells as inactive cytoplasmic precursors that
require cleavage by the enzyme caspase-1 in order to be released
from the cells. Experiments with caspase-1 inhibitors demon-
strated that aluminum adjuvants induce activation of caspase-1
resulting in the secretion of the active forms of IL-1β and IL-18
(Li et al., 2007; Sokolovska et al., 2007). Subsequent work showed
that the secretion of IL-1βand IL-18 by dendritic cells incubated
with aluminum adjuvants depends on the presence of the NOD-
like receptor NLRP3 (Eisenbarth et al., 2008; Franchi and Nunez,
2008; Hornung et al., 2008; Kool et al., 2008a; Li et al., 2008).
NLRP3 is a member of a family of cytoplasmic pattern recogni-
tion receptors and is activated in response to a variety of sterile
stimuli such as ATP, uric acid crystals, silica, asbestos, and alu-
minum adjuvants (Martinon et al., 2009). Upon activation,NLRP3
forms a multimeric protein complex termed inflammasome that
contains the adaptor protein apoptosis-associated speck-like pro-
tein (ASC) and the inactive precursor of caspase-1, procaspase-1.
The close proximity of procaspase-1 molecules leads to auto-
proteolytic processing into active caspase-1 that in turn cleaves
pro-IL-1β and pro-IL-18 into their active and secreted forms
(Martinon et al., 2009). Activation of NLRP3 by aluminum adju-
vants required phagocytosis of aluminum particles, acidification
of lysosomes, and maturation of cathepsin B (Eisenbarth et al.,
2008; Hornung et al., 2008). The aluminum particles caused dis-
ruption of the phagolysosomes and release of active cathepsin B
into the cytoplasm which may be a sufficient signal for NLPR3
activation (Hornung et al., 2008). Phagocytosis and activation of
cathepsin B in dendritic cells and macrophages can also lead to
discharge of ATP via connexin and pannexin channels into the
extracellular environment (Riteau et al., 2012). The extracellu-
lar ATP in turn binds to purinergic receptors including the P2X7
receptor which induces inflammasome activation. The in vivo rel-
evance of caspase-1 and NLRP3-dependent secretion of IL-1β and
IL-18 in the immunostimulatory effect of aluminum adjuvants
is controversial. Experiments with NLRP3-deficient mice have
demonstrated a marked suppression of antigen-specific IgE and
IgG1 production (Eisenbarth et al., 2008; Li et al., 2008), sup-
pression of IgE, but not IgG1 (Kool et al., 2008a), or no effect
on antibody production at all (Franchi and Nunez, 2008; McKee
et al., 2009). It is likely that these divergent results reflect differ-
ences in immunization protocols, type and amount of aluminum
adjuvants, and mouse strains. Aluminum adjuvants also induce
the secretion of IL-1α by dendritic cells in a caspase-1-dependent
manner (Sharp et al., 2009). IL-1α and IL-1β bind to the same IL-1
receptor and have overlapping functions. However, the secretion
of IL-1αwas only partially dependent on phagocytosis and NLRP3
suggesting that a different pathway is involved in the secretion of
this cytokine (Sharp et al., 2009). IL-1α, IL-1β, and IL-18 sig-
naling requires the adaptor protein MyD88 (Adachi et al., 1998).
The adjuvant effect of aluminum adjuvants in vivo is indepen-
dent of MyD88 suggesting a limited role for these cytokines in
immunostimulation by AH and AP (Schnare et al., 2001; Gavin
et al., 2006).
Another possible mechanism of dendritic cell activation by alu-
minum adjuvants is binding to plasma membrane lipids. This led
to reassortment of lipids and aggregation of lipid rafts resulting in
activation of the syk kinase and phosphoinositide-3 kinase (PI3K)
pathways (Flach et al., 2011). The lipid sorting resulted in abortive
phagocytosis and uptake of antigen, but not the aluminum adju-
vant. The authors suggested that the uptake of antigen via endo-
cytosis without adjuvant prevents cross-presentation and would
explain the ability of aluminum adjuvants to induce a humoral
and CD4 T cell response, but not a CTL response. However, as
discussed above, proteins combined with aluminum adjuvants
can in fact activate CD8 T cells (Kwissa et al., 2003; Serre et al.,
2010; MacLeod et al., 2011). Moreover, there is abundant evi-
dence of intracellular localization of aluminum in macrophages
and dendritic cells, both in vitro and in vivo (Rimaniol et al., 2004;
Morefield et al., 2005, 2008). Activation of PI3K also occurs fol-
lowing binding of ATP to the P2X7 receptor and is required for
inflammasome activation by extracellular ATP (Cruz et al., 2007).
Inhibition of PI3K partially inhibited the secretion of IL-1β by
dendritic cells (Mori et al., 2012).
Incubation of lipopolysaccharide (LPS)-activated macrophages
with aluminum adjuvants induced secretion of prostaglandin
E2 (PGE2; Kuroda et al., 2011). Damage of phagolysosomes
by phagocytized aluminum particles caused activation of Syk
and p38 MAP kinase pathways leading to the synthesis of
PGE2. Prostaglandin E synthase-deficient mice immunized with
OVA and aluminum adjuvant had decreased production of
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OVA-specific IgE, whereas the production of IgG1 and IgG2c were
similar to wild-type mice.
In addition to direct effects on dendritic cells, aluminum adju-
vants can also have indirect effects via endogenous activators.
Cell injury and necrosis cause the release of intracellular mol-
ecules that activate innate immune cells. These molecules have
been termed alarmins or danger-associated molecular patterns,
and include High Mobility Group Box 1 (HMGB1), uric acid,
ATP, heat shock proteins, DNA, IL-1α, and filamentous actin (Rock
et al., 2010; Ahrens et al., 2012; Zhang et al., 2012). Several recent
studies have suggested that uric acid, DNA, ATP, and HSP70 are
involved in the immunostimulation by aluminum adjuvants (Kool
et al., 2008b; Marichal et al., 2011; Riteau et al., 2012; Wang
et al., 2012). Intraperitoneal injection of aluminum-containing
adjuvant induced an increase of uric acid, and treatment of mice
with uricase decreased activation of antigen-specific T cells in the
draining lymph node suggesting a role for uric acid in the activa-
tion of the immune response by aluminum-containing adjuvants
(Kool et al., 2008b). Aluminum adjuvants are commonly used
for sensitization of mice in the establishment of mouse models
of allergic airway disease. The induction of allergic airway dis-
ease was impaired upon treatment with uricase implying a role of
uric acid in the development of the aluminum adjuvant induced
allergic immune response (Kool et al., 2011). However, as dis-
cussed above, aluminum adjuvants induce a weak cytotoxic T cell
response by themselves, whereas uric acid is a potent inducer of
CTLs (Shi et al., 2003). Moreover, the role of uric acid follow-
ing intramuscular injection of aluminum adjuvants remains to be
determined. Both intraperitoneal and intramuscular injection of
aluminum adjuvants with OVA induced cell death and release of
DNA (Marichal et al., 2011). OVA-specific secretion of IgE and
IgG1 following intraperitoneal injection was inhibited by treat-
ment with DNAse around the time of injection. Host cell DNA
itself acted as an adjuvant, and activated Th2 immune responses
via the transcription factor interferon regulatory factor 3 (IRF3).
Injection of IRF3-deficient mice with aluminum adjuvant induced
similar accumulation of inflammatory cells in the peritoneal cav-
ity and OVA-specific IgG1 as wild-type mice, but IRF3-deficiency
abolished the OVA-specific IgE response (Marichal et al., 2011),
suggesting a dissociation of the IgG1 and IgE response. Subcuta-
neous injection of aluminum-adjuvanted-OVA induced increased
expression of membrane HSP70 in splenic dendritic cells (Wang
et al., 2012). A similar effect was seen upon administration of
OVA with known stress-inducing compounds. Inhibition of the
function of HSP70 with a small molecule inhibitor in mice only
decreased the IgG2a response which suggests that HSP70 is pri-
marily involved with the induction of the weak Th1-component
of the immune response to aluminum-adjuvanted vaccines in
mice. This is consistent with the induction of predominant Th1
responses with HSP70 (Wang et al., 2002). Furthermore, HSP70
is a ligand of TLR4 (Vabulas et al., 2002), whereas the antibody
response to aluminum-adjuvanted vaccines is independent of
TLRs (Schnare et al., 2001; Gavin et al., 2006). This suggests a
minimal role of HSP70 in the immunostimulation by aluminum
adjuvants.
In summary, the formulation of vaccines with aluminum adju-
vants activate dendritic cells both directly and indirectly leading
to the differentiation of CD4 T cells into effector cells (Figure 2).
The relative roles of the direct and indirect mechanisms depend
on several factors, including the dose of aluminum in the vaccine,
dose volume, and route of injection.
ALUMINUM IN COMBINATION ADJUVANTS
A weakness of aluminum adjuvants is the failure to induce a robust
cell-mediated immune response which limits its utility in vac-
cines for diseases in which such an immune response is protective.
The addition of other immunostimulatory molecules to vaccines
can potentially overcome this limitation. The goal of such com-
bination adjuvants is to develop the “perfect mix” to achieve the
desired type and magnitude of an immune response (Guy, 2007).
When aluminum adjuvants are combined with other immunos-
timulatory molecules, the interactions are subject to the same
mechanisms that are involved with adsorption of antigens. The
adsorbed molecules are retained at the injection site which can pre-
vent potential systemic toxicity while increasing the interactions
with newly recruited antigen-presenting cells. However, too tight
adsorption through ligand exchange interferes with the activity of
the immunostimulatory molecules such as LPS and CpG oligonu-
cleotides (ODN; Shi et al., 2001b; Aebig et al., 2007). Adsorption
of immunostimulatory molecules to aluminum adjuvants can also
affect the adsorption of antigens (Aebig et al., 2007). Thorough
optimization of the formulation conditions is necessary to achieve
the most effective vaccine combination.
As aluminum adjuvants do not activate TLRs, the addition of
TLR agonists is a logical choice. A combination adjuvant com-
posed of AH and the TLR4 agonist MPLA is used in licensed
vaccines against hepatitis B and human papilloma virus (Garcon,
2010). MPLA is a derivative of LPS with greatly reduced toxicity.
LPS has two phosphates which allow binding with high affinity
to AH via ligand exchange and this neutralizes the activity of LPS
(Shi et al., 2001b). As the name implies, MPLA has one phosphate
which reduces the affinity for AH and enhances the adjuvant effect
of AH. The combination of AH with MPLA induces a stronger
antibody response and a shift from Th2 to Th1 cytokine produc-
tion in spleen cells (Giannini et al., 2006; Didierlaurent et al., 2009).
As mentioned earlier, the addition of MPLA to AH also enables
differentiation of activated CD8 T cells into CTLs (MacLeod et al.,
2011). The effect of other TLR agonists on the immune response
to aluminum-adjuvanted vaccines has been investigated, but this
has not yet led to licensed products. The TLR9 agonist CpG ODN
enhanced the antibody response in mice to hepatitis B antigen for-
mulated with AH with a shift from IgG1 to IgG2a antibodies, and
induced a CTL response (Davis et al., 1998). A similar enhance-
ment has been reported in people injected with AH-adjuvanted
hepatitis B vaccine with added CpG ODN (Cooper et al., 2004).
The CpG ODN bind more strongly to AH than AP and the binding
to AH is reduced in the presence of phosphate buffer suggesting
that ligand exchange underlies the adsorption to AH (Aebig et al.,
2007). Adsorption of CpG ODN is important for the enhance-
ment of the immune response and excess non-adsorbed CpG ODN
appears to inhibit the immune response (Mullen et al., 2007).
Muramyl dipeptide (MDP), a component of the mycobacte-
rial cell wall, activates the innate immune system via NOD2, a
cytoplasmic pattern recognition receptor. The combination of AH
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FIGURE 2 | Effect of aluminum adjuvants on dendritic cells. The
particulate nature of adsorbed protein (red) antigens facilitates
phagocytosis and antigen presentation (1). Uptake of aluminum adjuvants
may lead to destabilization and rupture of the phagolysosome (2) which
results in activation of cathepsin B (3). Cathepsin B induces the assembly
of the NLPR3 inflammasome directly (4) or via extracellular release of ATP
through connexin and pannexin channels (5). Caspase-1, a component of
the inflammasome, cleaves pro-IL-1β and IL-18 into active forms that are
released from the cell (6). Phagolysosome destabilization also induces the
secretion of PGE2 (7), and PGE2, IL-1β, and IL-18 all support the
differentiation of CD4 T cells into Th2 cells. Aluminum adjuvants also
directly interact with the lipid rafts in the cell membrane which results in
activation of the Syk and PI3-kinase signaling pathways (8). Injection of
aluminum-adjuvanted vaccines causes cell damage and necrosis with
release of uric acid, ATP, and DNA (9). These molecules in turn activate
dendritic cells (10). See the text for more details and references.
with MDP as adjuvant did not enhance the antibody response to
a bacterial antigen in comparison with AH alone, but it stimu-
lated a stronger IFN-γ response (Moschos et al., 2006). Quil A, a
partially purified mixture of saponins from the Quillaja saponaria
tree, activates NALP3 inflammasomes in dendritic cells similar to
aluminum adjuvants (Li et al., 2008). In spite of the overlapping
mechanism of dendritic cell activation, the combination of AH
and Quil A enhanced the antibody response and CTL response to
protein antigens in comparison with AH alone (Wu et al., 1992;
Lofthouse et al., 1995). However, Quil A failed to enhance the
immune response to a bacterial antigen when combined with AH
in another study (Moschos et al., 2006).
SAFETY OF ALUMINUM-CONTAINING ADJUVANTS
Aluminum-containing adjuvants have been used for more than
70 years in billions of doses of vaccines, and have an excellent
safety record (Butler et al., 1969; Edelman, 1980; Jefferson et al.,
2004). The maximum amount of aluminum adjuvant allowed in
human vaccines in the US is 0.85 mg Al/dose, and the amount in
licensed vaccines ranges from 0.125 to 0.85 mg Al/dose (Baylor
et al., 2002). Aluminum is an abundant metal in the environment
and is daily ingested in food and water (Willhite et al., 2012).
Aluminum is also commonly used in antacids and antiperspi-
rants. However, only small amounts of aluminum are absorbed
via the intestinal barrier and the skin. Most of the aluminum is
excreted via the kidneys. Aluminum toxicity from occupational
exposure, renal disease, and parenteral nutrition is associated with
neurologic disease and bone disease (Willhite et al., 2012). The
pharmacokinetics of aluminum following intramuscular injection
of AH and AP (0.85 mg/dose) was studied in rabbits using the rare
26Al isotope as a tracer (Flarend et al., 1997). The data indicated
that 17% of AH and 51% of AP was released into the blood circu-
lation over a 28 day period. Based on these and other data, it was
recently estimated that the concentration of aluminum in blood
derived from vaccines administered to infants during the first year
of life remains well below the minimum risk level established by the
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Agency for Toxic Substances and Disease Registry (Mitkus et al.,
2011).
As discussed above, injection of aluminum adjuvants induces a
local inflammatory reaction, and this can be associated with clin-
ical experiences of pain, swelling, and redness at the injection site.
These localized reactions are usually mild and of short duration.
In fact, aluminum adjuvants reduce the prevalence and severity of
systemic adverse reactions by binding and slowly releasing mol-
ecules thereby reducing toxicity. This has been demonstrated for
LPS which bind tightly to AH via ligand exchange involving the two
terminal phosphate groups neutralizing the activity (Norimatsu
et al., 1995; Shi et al., 2001b). The prevalence of systemic adverse
effects was greater in children immunized with plain DTP vac-
cine than in those receiving DTP with AH (Butler et al., 1969). In
allergen immunotherapy, subcutaneous injection of AH-adsorbed
allergen induced fewer local reactions than the allergen in solution
(Rueff et al., 2004).
The prevalence and severity of local inflammatory reactions
is affected by the site of injection. Local reactions were greater
following subcutaneous than intramuscular immunization of
aluminum-adjuvanted DT and anthrax vaccines (Mark et al.,
1999; Pittman et al., 2002). This can be attributed in part to
the superficial location of subcutaneous reactions, but can also
be the result of physiological differences between the tissues.
Casein tightly adsorbed to AH persisted at the injection site
longer following subcutaneous than intramuscular injection pos-
sibly reflecting differences in lymph flow rate between the subcutis
and skeletal muscle (Noe et al., 2010). Contact hypersensitivity
to aluminum is rare, but it has been reported following vac-
cination with aluminum-adjuvanted vaccines, hyposensitization
with aluminum-adjuvanted allergens and the use of aluminum-
containing antiperspirants (Bergfors et al., 2003; Netterlid et al.,
2009; Garg et al., 2010). It manifests itself by persistent itching nod-
ules and contact dermatitis to antiperspirants. The contact hyper-
sensitivity response can contribute to the inflammatory reaction
at the injection site.
A muscle disease termed macrophage myofasciitis character-
ized by muscle weakness, myalgia, and fever was attributed to
vaccination with aluminum-adjuvanted vaccines (Gherardi et al.,
1998). Biopsies of the deltoid muscle demonstrated accumula-
tion of macrophages with intracellular accumulation of aluminum
hydroxide. The patients had received vaccinations 3 months to
several years prior to the biopsy. The light microscopic lesions
are similar to those described at the injection site in people and
experimental animals injected intramuscularly with aluminum
adjuvants (Mrak, 1982; Verdier et al., 2005; Lach and Cupler,
2008). Such lesions have been demonstrated in non-human pri-
mates 12 months after injection (Verdier et al., 2005). There is no
evidence that these localized injection site reactions are related to
systemic muscle disease (Lach and Cupler, 2008).
In veterinary medicine, an increased prevalence of sarcomas in
cats was reported in the early 1990s (Hendrick et al., 1992). The
location, histologic features, and biological behavior suggested a
distinct type of tumor associated with the site of vaccination (Hen-
drick et al., 1994; Doddy et al., 1996). The prevalence is estimated
at about 1:3,000–1:10,000 vaccinations. Aluminum was identified
in some of the sarcomas that were present at sites of previous
vaccination in cats (Hendrick et al., 1992). This suggested a pos-
sible causal role of aluminum adjuvants in the development of
sarcomas, but subsequent epidemiologic studies failed to demon-
strate an association between particular types of vaccines and
sarcomas (Kass et al., 2003). However, a recent report indicated
that cats with sarcomas in the rear lower limb were less likely to
have received recombinant rabies vaccine without adjuvant than
an adjuvanted inactivated rabies vaccine (Srivastav et al., 2012).
Non-adjuvanted vaccines induced less severe inflammation than
adjuvanted vaccines at the subcutaneous injection site in cats (Day
et al.,2007). Sarcomas have also been reported in cats in association
with injections other than vaccines including long acting penicillin
and corticosteroid medications (Kass et al., 2003; Srivastav et al.,
2012). This suggests that there is a small subpopulation of cats that
is prone to develop sarcomas at sites of chronic inflammation, and
no specific role for aluminum adjuvant in the pathogenesis of these
neoplasms. There is no evidence of sarcomas caused by injection of
aluminum-adjuvanted vaccines or allergens in people (Jekel et al.,
1978).
CONCLUSION
Aluminum-containing adjuvants are widely used in preventive
vaccines against infectious diseases and in immunotherapy of
allergies. Recent studies have begun to increase our under-
standing of the mechanisms involved in adsorption of anti-
gens onto aluminum adjuvants and the effect of adsorption
on the stability of antigens and the immune response. Alu-
minum adjuvants appear to enhance the immune response via
several molecular pathways, but more work is needed to under-
stand the interactions and relative importance of these path-
ways. This knowledge will help to determine the optimal for-
mulation conditions for effective and safe aluminum-adjuvanted
vaccines.
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